Lenalidomida Stada (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, triggering degradation of transcription factors Ikaros and Aiolos. This leads to anti‑angiogenic, anti‑inflammatory, and immunomodulatory effects that suppress malignant cell growth and enhance immune‑mediated tumor clearance.

The specific dose of Lenalidomida Stada is determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Prescribers follow approved dosing guidelines and adjust as needed.

Lenalidomida Stada is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception. Safety during breastfeeding has not been established, so nursing is generally discouraged while on therapy.

To order Lenalidomida Stada, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lenalidomide and thalidomide belong to the same immunomodulatory class, but lenalidomide is more potent, has a better safety profile, and is approved for a broader range of hematologic cancers. Thalidomide is associated with higher rates of peripheral neuropathy and sedation, whereas lenalidomide shows fewer neurotoxic effects.

Lenalidomida Stada should be stored at ambient temperature, preferably below 25 °C, in the original blister or bottle. Keep the product away from moisture, direct sunlight, and excessive heat. Do not refrigerate or freeze the tablets.

Lenalidomida Stada is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, and the possible development of secondary primary malignancies. Patients should be monitored regularly for signs of clotting, infection, and new cancer diagnoses.

Lenalidomida Stada should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled active infections. Caution is also advised in those with severe renal or hepatic impairment, where dose adjustments may be required.